ClinicalTrials.gg
RecruitingNCT06325709Updated Nov 5, 2026

Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease

A Phase 1/2 interventional study of Campath and Sirolimus in Chronic Granulomatous Disease (CGD) and X-Linked Chronic Granulomatous Disease, sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Recruiting at 1 site in United States. Open to male participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by National Institute of Allergy and Infectious Diseases (NIAID) · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Granulomatous Disease, Chronic by National Institute of Allergy and Infectious Diseases (NIAID) — 7 open to participants now, 10 under way, none of them phase 3. Granulomatous Disease, Chronic · National Institute of Allergy and Infectious Diseases (NIAID).

Planned enrollment
10th of 24
15 · median 10
Started
2024
with 2 others
Phase 1/2
8 of 31
4 open now
Registered
30th of 31
by date

Among the 31 studies in Granulomatous Disease, Chronic by National Institute of Allergy and Infectious Diseases (NIAID), this one is the 10th largest by planned enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2024, is one of 8 in phase 1/2, and was the 30th registered.

Granulomatous Disease, Chronic

79 studies on the registry are indexed under Granulomatous Disease, Chronic; 17 are open to participants now.

Browse Granulomatous Disease, Chronic studies →

Open to participants now

7 of the 31 studies in Granulomatous Disease, Chronic by National Institute of Allergy and Infectious Diseases (NIAID) are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 12 Granulomatous Disease, Chronic studies recruiting now, 3 (25%) set no upper age limit and 9 (75%) stop at 75 or younger; 8 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 75 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Granulomatous Disease, Chronic by National Institute of Allergy and Infectious Diseases (NIAID), or all of them as a file.
02

Study summary

Background:

Chronic granulomatous disease (CGD) is a rare immune disorder caused by a mutation in the CYBB gene. People with CGD have white blood cells that do not work properly and are at greater risk of getting infections. Researchers want to know if gene therapy using the patient's own base-edited stem cells can improve the white cells' functioning and result in fewer CGD-related infections.

Objective:

To learn if base-edited stem cells will correct the white blood cells in people with CGD.

Eligibility:

Males aged 18 years and older with X-linked CGD.

Design:

This is a non-randomized study. Participants with the specific mutation under study will be screened during the initial phase.

During the development phase, participants will undergo apheresis to collect stem cells for base-editing correction of the mutation.

During the treatment phase, participants will first receive Campath (alemtuzumab) to reduce the risk of an immune response to the new protein expressed by the base-edited cells. This will be followed by conditioning chemotherapy with busulfan and subsequent infusion of the base-edited stem cells. Participants will be maintained on sirolimus to further reduce the risk of an immune response to the new protein expressed by the base-edited cells.

Follow-up visits will continue for 15 years.

Read the detailed description

Study Description:

Open-label, phase 1/2 trial to determine the safety, and efficacy of a single infusion of base-edited (BE) autologous hematopoietic stem and progenitor cells (HSPCs) for treatment of X-linked chronic granulomatous disease (X-CGD). Base editing is performed to repair CYBB missense gene mutations (eg, CYBB c.676C>T). The study hypotheses are that 1) base editing can efficiently repair gene mutations in HSPCs; and 2) BE HSPCs can engraft and differentiate into functional phagocytes with restored nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity.

During the initial development phase each study participant will undergo apheresis for CD34+ HSPC collection for the development and validation of a mutation-specific BE system.

During the treatment phase, participants will receive a one-time infusion of the BE autologous HSPC (study product) after the administration of Campath (alemtuzumab) and of busulfan conditioning (total 12 mg/kg with a targeted total AUC of 65,000 ng/mL x hr). Sirolimus will be initiated on Day -1 and may be given for approximately 3-6 months.

Participants will have follow-up evaluations at months 3, 6, 12, 18, and 24, and yearly thereafter until 5 years after treatment. Key study assessments include adverse event (AE) assessment, blood laboratory evaluations of functional protein made from the target gene (CYBB, encodes for gp91\^phox), and deoxyribonucleic acid (DNA) sequencing to identify rates of gene repair and off-target mutation.

The final study follow-up under this protocol will be at 5 years, but long-term follow-up under a separate NIH protocol will continue annually to 15 years after treatment.

Objectives:

Primary Objectives:

  • To evaluate the safety of BE autologous CD34+ cells.
  • To evaluate the efficacy of BE autologous CD34+ cells.

Secondary Objectives:

-To evaluate:

  • Efficiency of base editing (percentages of target nucleotide conversion).
  • Engraftment capability of BE HSPCs.
  • Efficiency in restoring gp91\^phox expression
  • Efficiency in restoring NADPH oxidase function.
  • Clinical efficacy.
  • Stability of gene correction.

Exploratory Objectives:

-To evaluate:

  • Specificity of base editing by assessing rates of off-target edits at top predicted sites.
  • Random off-target edits by whole genome sequencing (WGS).

Endpoints:

Primary Endpoints:

  • Safety of gene therapy using BE autologous HSPCs as measured by study product-related AEs and serious AEs (SAEs) through 2 years after treatment.
  • Efficacy of gene therapy determined as percentages of subjects who have >= 10% oxidase-positive granulocytes at 12 months after infusion.

Secondary Endpoints:

  • Determine frequency of converted target nucleotide alleles.
  • Assess the frequency of gene-modified alleles compared to infusion product in peripheral blood at 12 months.
  • Evaluate efficacy of restoring gp91\^phox expression.
  • Evaluate efficacy of NADPH oxidase functional restoration as measured by the dihydrorhodamine (DHR) flow cytometry oxidase assay at 12 months after treatment (>=10% oxidase-positive neutrophils), or by quantitative measurement of reactive oxygen species (ROS) using the ferricytochrome C assay on peripheral blood granulocytes.
  • Evaluate clinical benefit by improvement of baseline clinical problems such as recurrent infections, growth failure, malnutrition, inflammatory bowel disease, or antibiotic usage.
  • Assess stability of gene correction by serial measurement of percent of nucleotide-converted alleles.

Exploratory Endpoints:

  • Evaluate specificity by assessing for off-target edits at predicted sites with high-throughput sequencing of the 5 most common candidate off-target loci identified by a comprehensive in vitro screen, Circularization for High-throughput Analysis of Nuclease Genome-wide Effects by sequencing (CHANGE-seq-BE), in peripheral blood cells.
  • Determine rate of random off-target edits WGS.
03

Conditions studied

  • Chronic Granulomatous Disease (CGD)
  • X-Linked Chronic Granulomatous Disease

Keywords

  • base editing
  • Gene Editing
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

->= 18 years of age.

  • Confirmed CYBB c.676 C>T mutation.
  • Male patients.
  • Clinically stable and eligible to undergo apheresis and conditioning chemotherapy.

    ->=5 x 10\^6 cryopreserved cells/kg body weight available for study product manufacturing.

  • History of at least one prior serious infection or inflammatory complication requiring hospitalization despite conventional therapy.
  • In the experience of a qualified clinical investigator, the patient has a poor prognosis.
  • Able and willing to use a highly effective method of , AND partner has communicated her willingness through subject to do same, if engaging in potentially reproductive sex from the signing of the and for 6 months after IMP infusion. Acceptable methods of contraception include the following:

    • Hormonal contraception in continuously effective use by female partner.
    • Male or female condom with spermicide as indicated.
    • Diaphragm or cervical cap in consistent and effective pattern of use with a spermicide by female partner.
    • Intrauterine device in-situ throughout above period by female partner.

Exclusion criteria

EXCLUSION CRITERIA:

Individuals meeting any of the following criteria will be excluded from study participation:

  • Untreated, acute infection.
  • Elevated anti-gp91 specific autoantibodies >2 x
  • Elevated anti-gp91 specific T cells (>10 fold)
  • Anti- antibody screening with >1 anti-platelet antibody positive in the presence of an ongoing brain infection; OR >1 anti-platelet antibody positive and considered unsafe for study participation after consultation with hematology specialist.
  • Known to busulfan or any component of the product.
  • for administration of busulfan.
  • Any current or pre-existing hematologic .
  • Chronic infections that are considered unsafe for participation in the study by Infectious Disease Consultant.
  • Cardiac abnormalities and neurological abnormalities that are deemed unsafe to participate in the study.
  • Childhood malignancy (occurring before 18 years of age) in the patient or a first degree relative, or previously diagnosed known genotype of the participant conferring a predisposition to cancer (no DNA or other testing for cancer predisposition genes will be performed as part of the screen for this protocol).
  • Hematological parameters unsafe for apheresis or above Grade 2 (CTCAE) criteria until improved.
  • Hepatic dysfunction- (ALT >3.0 - 5.0 x upper limit of normal [ULN]), aspartate aminotransferase (AST >3.0 - 5.0 x ULN), (>1.5 - 3.0 x ULN).
  • Renal dysfunction-serum creatinine >1.5 - 3.0 x ULN or 59-30 mL/min/1.73 m\^2.
  • Coagulation dysfunction- Prothrombin or Partial thromboplastin time >2 x ULN (patients on controlled anticoagulation agents will not be excluded for therapeutic levels).
  • Uncontrolled hypertension- Systolic BP 140-159 mm Hg or diastolic BP 90-99 mm Hg.
  • Abnormal blood chemistries- Hyperkalemia (K >5.5 - 6.0 mmol/L), Hypokalemia (\<LLN - 3.0 mmol/L and requiring intervention); OR Hypercalcemia (corrected serum calcium >11.5 - 12.5 mg/dL), Hypocalcemia (corrected serum calcium \<8.0 -7.0 mg/dL)

These values exclude false abnormalities secondary to hemolysis.

  • Cytogenetic abnormalities evidenced on bone marrow aspirate.
  • Pulmonary dysfunction \<25% predicted.
  • Previous treatment with gene therapy or gene editing products.
  • Previous receipt of non-HLA matched donor granulocyte transfusions.
  • Any other condition that, in the opinion of the investigator, may unduly compromise the safety or compliance of the patient, or would make successful study completion highly unlikely.
  • Unwilling to submit their information as part of the alemtuzumab (Campath(R)) Distribution Program application or the Distribution Program committee has determined the participant is not qualified to receive alemtuzumab.

NOTE: Alemtuzumab (campath) is no longer distributed commercially. To receive product, the physician must contact the program for the participant. If the participant is not willing to consent to submit their info (demographics, contact information, and rationale for use) to the program such that we can obtain the drug, then we cannot proceed with conditioning; therefore, no gene therapy will occur on this protocol.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Single Arm Study

    Drug: Campath · Drug: Sirolimus · Biological: Base-edited hematopoietic stem and progenitor cells · Drug: Busulfan · Drug: Palifermin · Drug: Filgrastim · Drug: Plerixafor

Interventions

  • DrugAlemtuzumabStudies of AlemtuzumabAlemtuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Immunomodulating agent: Daily subcutaneous administration beginning Day -9 for 5 days to reduce the risk of an immune response to the protein expressed by the BE HSPCs.

  • Immunomodulating agent: Daily oral dosing beginning Day -1 for approximately 3 to 6 months to reduce the risk of an immune response to the protein expressed by the BE HSPCs.

  • BiologicalBase-edited hematopoietic stem and progenitor cells

    Investigational/Study Agent: Base-edited autologous CD34 plus hematopoietic stem and progenitor cell product. The product is administered intravenously as a single infusion. This product is under an IND.

  • Transplant Conditioning Agent: An alkylating chemotherapy drug to enhance engraftment of the study agent (base-edited stem cells). Conditioning will be given intravenously over 3 days with an approximate total dose of 12mg/kg. Drug levels obtained will be obtained to achieve the targeted total busulfan AUC of 65,000 ng/mL x hr.

  • DrugFibroblast Growth Factor 7Studies of Fibroblast Growth Factor 7Fibroblast Growth Factor 7 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Mucositis Prophylaxis Agent: Intravenous infusion of keratinocyte growth factor (Palifermin) at 60 mcg/kg/day before (Days -7 to Day -5 administration of busulfan and (Days 1 to 3) post-busulfan administration to prevent oral mucositis.

  • Stem Cell Mobilizing Agent: Subcutaneous administration for 6 consecutive days. It is necessary to mobilize stem cells for collection.

  • Stem Cell Mobilizing Agent: Subcutaneous administration for 2 consecutive days to improve stem cell collection.

06

What researchers measure

Primary outcomes

  1. To evaluate the safety of base-edited autologous CD34+ cells

    Safety of gene therapy using base-edited autologous hematopoietic stem and progenitor cells as measured by study agent related adverse events and serious adverse events

    Time frame: Initiated from the time of the infusion of base-edited cells through 2 years post-infusion

  2. To evaluate the efficacy of base-edited autologous CD34+ cells

    Efficacy of gene therapy as determined by percentages ofparticipants who have \>= 10 percent oxidase-positive granulocytes

    Time frame: Assessed 12 months post-infusion of base-edited cells

Secondary outcomes

  1. Evaluate the efficiency of base-editing.

    Measure the percentages of gp91-expressing cells

    Time frame: Assessed 12-24 months post-infusion of base-edited cells

  2. Evaluate the engraftment capability of base-edited hematopoietic stem progenitor cells.

    Measure the percentages of edited myeloid cells

    Time frame: Assessed 12-24 months post-infusion of base-edited cells

  3. Evaluate the efficiency in restoring gp91phox expression.

    Measure the frequency of gp91phox+ cells and the amount of gp91phox protein

    Time frame: Assessed 12-24 months post-infusion of base-edited cells

  4. Evaluate efficacy in restoring NADPH oxidase function.

    Measure the frequency of DHR+ cells

    Time frame: Assessed 12-24 months post-infusion of base-edited cells

  5. Evaluate clinical efficacy

    Assess the frequency of infections and progression of co-morbidities of CGD

    Time frame: Assessed through study completion

  6. Evaluate the stability of gene correction

    Compare frequencies of corrected alleles before infusion and at study completion

    Time frame: Assessed through study completion

07

Study locations

1 of 1 sites recruiting
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
    Recruiting
    • NIH Clinical Center Office of Patient Recruitment (OPR) · Contactccopr@nih.gov · 800-411-1222
    • Suk See De Ravin, MD · Contactsderavin@mail.nih.gov · (301) 496-6772
08

References and documents

Publications

  • Komor AC, Badran AH, Liu DR. Editing the Genome Without Double-Stranded DNA Breaks. ACS Chem Biol. 2018 Feb 16;13(2):383-388. doi: 10.1021/acschembio.7b00710. Epub 2017 Oct 9. PubMed 28957631 ↗
  • Kuhns DB, Alvord WG, Heller T, Feld JJ, Pike KM, Marciano BE, Uzel G, DeRavin SS, Priel DA, Soule BP, Zarember KA, Malech HL, Holland SM, Gallin JI. Residual NADPH oxidase and survival in chronic granulomatous disease. N Engl J Med. 2010 Dec 30;363(27):2600-10. doi: 10.1056/NEJMoa1007097. PubMed 21190454 ↗
  • Bzhilyanskaya V, Ma L, Liu S, Fox LR, Whittaker MN, Meis RJ, Choi U, Lawson A, Ma M, Theobald N, Burkett S, Sweeney CL, Lazzarotto CR, Tsai SQ, Lack JB, Wu X, Dahl GA, Malech HL, Kleinstiver BP, De Ravin SS. High-fidelity PAMless base editing of hematopoietic stem cells to treat chronic granulomatous disease. Sci Transl Med. 2024 Oct 16;16(769):eadj6779. doi: 10.1126/scitranslmed.adj6779. Epub 2024 Oct 16. PubMed 39413163 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2024 (actual). Primary completion is estimated for Dec 2032, 104 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2024
First posted
Mar 22, 2024
StartActual
Apr 17, 2024
Primary completionEst.
Dec 31, 2032
CompletionEst.
Dec 31, 2032
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: description
2 updates, last Nov 5, 2026
Show all 2 updates
  1. Nov 5, 2026
    Minor edits only
    + 1 other change: description
  2. Nov 3, 2026
    Minor edits only
    + 1 other change: description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06325709
Responsible party
Sponsor
First posted
Mar 22, 2024
Start date
Apr 17, 2024
Primary completion
Dec 31, 2032 (estimated)
Completion
Dec 31, 2032 (estimated)
Last update
Nov 5, 2026

Study contacts

Suk S De Ravin, M.D.
Contact
sderavin@mail.nih.gov
(301) 496-6772
Suk S De Ravin, M.D.
principal investigator · National Institute of Allergy and Infectious Diseases (NIAID)

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Alemtuzumab · Sirolimus · Busulfan · Fibroblast Growth Factor 7 · Filgrastim · Plerixafor

Start the discussion